Global Hypercholesterolemia Drugs Market 2016-2020 - Product Image

Global Hypercholesterolemia Drugs Market 2016-2020

  • ID: 3795210
  • Report
  • Region: Global
  • 98 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • AtheroNova
  • Cipla
  • Eli Lilly
  • Laboratoires
  • Novartis
  • MORE
About Hypercholesterolemia

Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C. LDL carries cholesterol to the body and HDL removes cholesterol from the cells by reversing cholesterol transport to the liver.

The analysts forecast the global hypercholesterolemia drugs market to decline at a CAGR of 6.78% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypercholesterolemia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generics, and off-label drugs used to treat hypercholesterolemia.

The market is divided into the following segments based on geography:

- Americas
- APAC
- EMEA

The report, Global Hypercholesterolemia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AbbVie
- Aegerion Pharmaceuticals
- AstraZeneca
- Merck
- Pfizer
- Sanofi

Other prominent vendors
- Alnylam Pharmaceuticals
- Amarin
- Amgen
- AtheroNova
- Aurobindo Pharma
- Biocon
- Biospherics
- Bristol-Myers Squibb
- Catabasis Pharmaceuticals
- Cerenis Therapeutics
- Cipla
- CJ HealthCare
- CKD Bio
- Concord Biotech
- CymaBay Therapeutics
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Eli Lilly
- Esperion Therapeutics
- GlaxoSmithKline
- HanAll BioPharma
- JW Pharmaceuticals
- Kadmon Pharmaceuticals
- Kowa Company
- Laboratoires
- Livzon Pharmaceutical
- Lupin Pharmaceuticals
- Madrigal Pharmaceuticals
- Merz Pharmaceuticals
- Mylan
- Novartis
- Regeneron Pharmaceuticals
- ReGenX Biosciences
- Santaris Pharma
- Serometrix
- Sun Pharmaceutical
- Arbutus Biopharma
- Teva Pharmaceuticals
- Torrent Pharmaceuticals
- Zydus Cadila

Market drivers
- Rising prevalence of chronic diseases

Market challenges
- Loss of patent exclusivity of branded therapies

Market trends
- Expected entry of cost-effective OTC versions

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • AtheroNova
  • Cipla
  • Eli Lilly
  • Laboratoires
  • Novartis
  • MORE
PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
  • Drug profiles
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
  • Clinical application
  • Treatment guidelines
  • Key buying criteria
PART 05: Hypercholesterolemia: An overview
  • History of hypercholesterolemia
  • Hypercholesterolemia management market dynamics
  • Hypercholesterolemia prescription landscape
  • Management of hypercholesterolemia
  • Epidemiology
  • Unmet medical needs and role of PCSK9 and CETP inhibitors
PART 06: Pipeline portfolio
  • Information on pipeline candidates
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Segmentation by type of disease
  • FH
  • Non-FH
PART 09: Market segmentation by MOA
  • HMG-CoA reductase inhibitors
  • Fibric acid derivatives
  • Nicotinic acid
  • Bile acid sequestrants
  • Other
PART 10: Market segmentation by drug class
  • Statins
  • Non-statins
PART 11: Geographical segmentation
  • Global hypercholesterolemia drugs market by geographical segmentation 2015-2020
  • Hypercholesterolemia drugs market in Americas
  • Hypercholesterolemia drugs market in EMEA
  • Hypercholesterolemia drugs market in APAC
PART 12: Market drivers
  • Increasing risk of CVDs
  • Rising prevalence of chronic diseases
  • Promising pipeline of drugs
  • Change in ATP guidelines for management of hypercholesterolemia
  • Growing older population
PART 13: Impact of drivers

PART 14: Market challenges
  • Loss of patent exclusivity of branded therapies
  • Drawbacks associated with current therapies
  • High cost of therapy
  • Stringent regulatory guidelines
  • Lack of proper diagnosis
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Expected entry of cost-effective OTC versions
  • Increasing use of statins
  • Increased use of combination therapies
  • Consideration of lifestyle management in ATP guidelines
PART 17: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
PART 18: Key vendor analysis
  • AbbVie
  • Aegerion Pharmaceuticals
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • Other prominent vendors
PART 19: Appendix
  • List of abbreviations
PART 20: About the Author

List of Exhibits

Exhibit 01: Product offerings
Exhibit 02: Different class of lipoproteins
Exhibit 03: Evaluation of lipoprotein levels based on ATP III classification
Exhibit 04: Key buying criteria for hypercholesterolemia drugs
Exhibit 05: Timeline of cholesterol lowering drugs
Exhibit 06: Market dynamics for hypercholesterolemia
Exhibit 07: Prescription landscape for statins 2015
Exhibit 08: Prescription landscape for ezetimibe 2015
Exhibit 09: Prescription landscape for other classes 2015
Exhibit 10: Distribution of cholesterol-lowering medication for individuals above 40 years
Exhibit 11: Percentage use of prescription cholesterol-lowering medication in US for various indications 2015
Exhibit 12: Treatment of hypercholesterolemia
Exhibit 13: Pharmacological treatment of hypercholesterolemia
Exhibit 14: High cholesterol levels by race and ethnicity in US 2015
Exhibit 15: PCSK9 inhibitors in preclinical and clinical development 2015
Exhibit 16: Pipeline portfolio: Global hypercholesterolemia drugs market
Exhibit 17: Pipeline share of hypercholesterolemia drugs
Exhibit 18: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
Exhibit 19: Five forces analysis
Exhibit 20: Classification of hyperlipidemia
Exhibit 21: Global hypercholesterolemia market segmentation by MOA
Exhibit 22: Global hypercholesterolemia market segmentation by MoA 2015
Exhibit 23: Global hypercholesterolemia drugs market segmentation by drug class
Exhibit 24: Global hypercholesterolemia drugs market by drug class 2015 (% share)
Exhibit 25: Hypercholesterolemia drugs market revenue by drug class 2015-2020 ($ billions)
Exhibit 26: Global statin market 2015-2020 ($ billions)
Exhibit 27: Number of prescriptions for statins in US
Exhibit 28: Usage of statins for hypercholesterolemia in US 2015
Exhibit 29: Usage of statins for hypercholesterolemia in UK 2015
Exhibit 30: Global non-statins market 2015-2020 ($ billions)
Exhibit 31: Number of prescriptions for non-statins in US
Exhibit 32: Global hypercholesterolemia drugs market: YoY growth and revenue based on drug class 2015-2020
Exhibit 33: Segmentation of global hypercholesterolemia drugs markets by geography 2015
Exhibit 34: Hypercholesterolemia drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 35: Percentage share of hypercholesterolemia drugs market by geography 2015-2020 (%)
Exhibit 36: Hypercholesterolemia drugs market in Americas 2015-2020 ($ billions)
Exhibit 37: Share of hypercholesterolemia drugs market in Americas by country 2015
Exhibit 38: Hypercholesterolemia drugs market in EMEA 2015-2020 ($ billions)
Exhibit 39: Hypercholesterolemia drugs market in APAC 2015-2020 ($ billions)
Exhibit 40: Global hypercholesterolemia drugs market: YoY growth and revenue based on geography 2015-2020
Exhibit 41: Population aged 60 years and over: World, developed and developing regions ($ millions)
Exhibit 42: Impact of drivers
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Arguments for and against OTC switch by pharmaceutical companies and regulatory organizations
Exhibit 45: Market share analysis of global hypercholesterolemia drugs market 2015
Exhibit 46: Revenue from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
Exhibit 47: AbbVie: YoY revenue and growth rate of lipid franchise portfolio 2013-2015 ($ millions)
Exhibit 48: Key takeaways
Exhibit 49: Aegerion: YoY revenue and growth rate of JUXTAPID 2013-2015 ($ millions)
Exhibit 50: Key takeaways
Exhibit 51: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
Exhibit 52: AstraZeneca: Geographic segmentation of Crestor 2015 by revenue
Exhibit 53: Key takeaways
Exhibit 54: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
Exhibit 55: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
Exhibit 56: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
Exhibit 57: Merck: Key takeaways
Exhibit 58: Pfizer: YoY revenue and growth rate of Lipitor 2013-2015 ($ billions)
Exhibit 59: Pfizer: Geographic segmentation of Lipitor by revenue 2015
Exhibit 60: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
Exhibit 61: Key takeaways
Exhibit 62: Sanofi: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • AtheroNova
  • Cipla
  • Eli Lilly
  • Laboratoires
  • Novartis
  • MORE
New Report Released: - Global Hypercholesterolemia Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the global hypercholesterolemia drugs market: AbbVie, Aegerion Pharmaceuticals, AstraZeneca, Merck, Pfizer, and Sanofi.

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarin, Amgen, AtheroNova, Aurobindo Pharma, Biocon, Biospherics, Bristol-Myers Squibb, Catabasis Pharmaceuticals, Cerenis Therapeutics, Cipla, CJ HealthCare, CKD Bio, Concord Biotech, CymaBay Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Eli Lilly, Esperion Therapeutics, GlaxoSmithKline, HanAll BioPharma, JW Pharmaceuticals, Kadmon Pharmaceuticals, Kowa Company, Laboratoires, Livzon Pharmaceutical, Lupin Pharmaceuticals, Madrigal Pharmaceuticals, Merz Pharmaceuticals, Mylan, Novartis, Regeneron Pharmaceuticals, ReGenX Biosciences, Santaris Pharma, Serometrix, Sun Pharmaceutical, Arbutus Biopharma, Teva Pharmaceuticals, Torrent Pharmaceuticals, and Zydus Cadila.

Commenting on the report, an analyst from the research team said: “One of the major trends for market growth will be the increased use of combination therapies. Combinations of drugs are often used to treat conditions and they are mostly useful in managing lipid abnormalities. Combination therapies have advantages over monotherapies in terms of efficacy and a reduced incidence of adverse effects. Further, combination therapies have lesser manufacturing costs compared to the costs of manufacturing monotherapies administered concurrently, simpler logistics of distribution, and improved patient compliance by reducing the pill burden. Combination therapy in fixed dose combinations containing a statin and another lipid-lowering drug is available in the market.”

According to the report, one of the key drivers for market growth will be rising prevalence of chronic diseases. Chronic conditions such as obesity and diabetes are linked to lipid abnormalities and are a result of health risk behaviors. For instance, the prevalence of obesity has doubled between 1980 and 2014. In 2014, over 1.9 billion individuals were found to be overweight. Of these, over 600 million were obese. In the same year, the global prevalence of diabetes in individuals over 18 years of age was estimated to be 9%. According to a WHO report published in 2014, the global prevalence of diabetes was 8% in 2011 and is expected to rise to 10% by 2030. Regular use of anti-hypercholesterolemia drugs is necessary to lower cholesterol levels and reduce the risk of CVDs.

Further, the report states that stringent regulatory guidelines will be one of the major challenges for the market. The drug approval process across the globe is a stringent process demanding evidence from clinical trial studies. The regulatory authorities carefully study and evaluate the drug related data before approving it for use. The regulatory bodies examine some major factors such as safety, efficacy, carcinogenicity, mitogenicity, pharmacological data, pharmacodynamics effects, and drug interactions. Thus, a drug failing in any of these criteria is likely to receive a complete response letter (CRL) or be rejected by the regulatory agencies. On receiving a CRL, the drug applicant is required to furnish additional data pertaining to the drug. This, in turn, might require additional clinical trials and might increase the R&D expenditure for the drug.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
- AbbVie
- Aegerion Pharmaceuticals
- AstraZeneca
- Merck
- Pfizer
- Sanofi
- Alnylam Pharmaceuticals
- Amarin
- Amgen
- AtheroNova
- Aurobindo Pharma
- Biocon
- Biospherics
- Bristol-Myers Squibb
- Catabasis Pharmaceuticals
- Cerenis Therapeutics
- Cipla
- CJ HealthCare
- CKD Bio
- Concord Biotech
- CymaBay Therapeutics
- Daewoong Pharmaceutical
- Daiichi Sankyo
- Eli Lilly
- Esperion Therapeutics
- GlaxoSmithKline
- HanAll BioPharma
- JW Pharmaceuticals
- Kadmon Pharmaceuticals
- Kowa Company
- Laboratoires
- Livzon Pharmaceutical
- Lupin Pharmaceuticals
- Madrigal Pharmaceuticals
- Merz Pharmaceuticals
- Mylan
- Novartis
- Regeneron Pharmaceuticals
- ReGenX Biosciences
- Santaris Pharma
- Serometrix
- Sun Pharmaceutical
- Arbutus Biopharma
- Teva Pharmaceuticals
- Torrent Pharmaceuticals
- Zydus Cadila
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll